Sign In
Buy MESO
$15.09
+0.324 (+2.19%)
At Close: Nov 17, 2025
James M. O'Brien Appointed Chief Financial Officer at Mesoblast
01:52am, Monday, 17'th Nov 2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with
Bears are Losing Control Over Mesoblast Limited (MESO), Here's Why It's a 'Buy' Now
10:56am, Monday, 10'th Nov 2025
After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estima
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
06:40pm, Tuesday, 04'th Nov 2025
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Dru
All You Need to Know About Mesoblast Limited (MESO) Rating Upgrade to Buy
01:01pm, Wednesday, 29'th Oct 2025
Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
07:48pm, Sunday, 19'th Oct 2025
NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
07:24pm, Monday, 06'th Oct 2025
NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:09am, Monday, 06'th Oct 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Monday.
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
09:04pm, Thursday, 02'nd Oct 2025
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthca
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
01:49am, Friday, 26'th Sep 2025
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic ce
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
09:18pm, Sunday, 14'th Sep 2025
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercia
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
09:47pm, Wednesday, 03'rd Sep 2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into con
Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript
12:27pm, Friday, 29'th Aug 2025
Mesoblast Limited (NASDAQ:MESO ) Q4 2025 Earnings Conference Call August 28, 2025 6:30 PM ET Company Participants Andrew Chaponnel - Interim Chief Finance Officer Marcelo Santoro - Chief Commercial Of
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
08:24pm, Thursday, 28'th Aug 2025
Financial Results and Operational Update for the Full Year Ended June 30, 2025 Financial Results and Operational Update for the Full Year Ended June 30, 2025
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
01:01pm, Tuesday, 22'nd Jul 2025
Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rally
12:52pm, Monday, 21'st Jul 2025
Shares in Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) surged by nearly 38% following Friday’s successful commercial launch of its FDA-approved treatment, Ryoncil®, for steroid-refractory acute graft-versu
